Search results
PROMOTED
How do worsening heart events dictate the long-term outcomes of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and can earlier intervention influence the disease trajectory in ATTR-CM? In this new sub-analysis from ATTRibute-CM, recorded onsite at ESC Heart Failure Congress (HFA) 2026, Prof Marianna Fontana (University College London, London, UK) sheds further light onto these…
View more
HFA 2026: Updates on ATTR-CM
Author(s):
Marianna Fontana
,
Added:
3 weeks ago
Video Series
Author(s):
Babar Basir
,
Karim Al-Azizi
Added:
2 months ago
ACC 2026 — Drs Karim Al-Azizi (Baylor Scott & White The Heart Hospital, Plano) and Babar Basir (Henry Ford Hospital, US) deliver a short, front-line interventional view of the STEMI Door-to-Unload (STEMI-DTU) trial (NCT03000270), making this an efficient 5-minute update for cardiologists and cath lab teams.STEMI-DTU randomised haemodynamically stable patients aged 18–85 years with a first acute…
View more
Author(s):
Andrea Barucci
,
Valentina Colcelli
,
Salvatore De Masi
,
et al
Added:
4 months ago
Author(s):
Ton Duy Mai
,
Tri Huynh Quang Ho
,
Sy Van Hoang
,
et al
Added:
1 year ago
Author(s):
Deepak L Bhatt
Added:
2 months ago
ACC 2026 — Dr Deepak Bhatt (Mount Sinai Fuster Heart Hospital, US) delivers his expert verdict on three late-breaking clinical trials from ACC 2026 that are poised to influence cardiovascular care and future clinical guidelines.Dr Bhatt highlights data updates from the SURPASS-CVOT trial, exploring expanded cardiometabolic findings with tirzepatide versus dulaglutide, discusses the HI-PEITHO…
View more
Author(s):
Navin K Kapur
Added:
2 months ago
ACC.26 – Dr Navin Kapur (Tufts Medicine, Boston, MA, US) joins us to discuss findings from the STEMI-Door To Unload (DTU) randomised clinical trial, examining whether primary left ventricular unloading with the Impella CP® device prior to reperfusion can reduce infarct size and heart failure-related outcomes in patients presenting with anterior ST-elevation myocardial infarction.This prospective,…
View more
Author(s):
Luigi Di Biase
Added:
4 months ago
Arrhythmia Academy Editor-in-Chief Dr Luigi Di Biase shares his expert perspective on the most practice-changing clinical trials emerging from the latest advances in atrial fibrillation management.In this highlights discussion, Dr Di Biase distills the key evidence that is reshaping clinical decision-making in AF ablation, anticoagulation strategies, and rhythm control approaches. Drawing from…
View more
Author(s):
Jaspal Singh Gill
,
Viral Sagar
,
Mark M Gallagher
Added:
4 months ago
Author(s):
Mirvat Alasnag
Added:
7 months ago
TCT 2025 - In this insightful highlights video from TCT 2025, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, SA) provides expert commentary on the most impactful late-breaking clinical trials presented at this year's conference.The commentary distills the most important late-breaking trials in structural cardiology, coronary interventions, and artificial intelligence presented at TCT 2025…
View more
Author(s):
Michael J Mack
Added:
7 months ago
TCT 2025 - Long-term follow-up of the PARTNER 3 trial showed no safety concerns for transcatheter aortic-valve replacement (TAVR) compared to surgical treatment of aortic stenosis (AS).Dr Michael Mack (Baylor Scott & White Heart Hospital, Plano, US) joins us to share the clinical and echocardiographic outcomes from the seven-year follow-up of the PARTNER 3 low-risk randomised trial (NCT02675114)…
View more